vs
Gaming & Leisure Properties, Inc.（GLPI）与Prestige Consumer Healthcare Inc.（PBH）财务数据对比。点击上方公司名可切换其他公司
Gaming & Leisure Properties, Inc.的季度营收约是Prestige Consumer Healthcare Inc.的1.5倍（$420.0M vs $283.4M），Gaming & Leisure Properties, Inc.净利率更高（57.0% vs 16.5%，领先40.5%），Gaming & Leisure Properties, Inc.同比增速更快（6.3% vs -2.4%），过去两年Gaming & Leisure Properties, Inc.的营收复合增速更高（5.0% vs 1.2%）
博彩与休闲地产公司（GLPI）是一家专注于赌场物业的房地产投资信托（REIT），总部位于宾夕法尼亚州怀奥米辛。公司于2013年11月从宾州国民娱乐分拆成立，目前持有62处赌场物业，全部对外出租给其他企业运营。
Prestige Consumer Healthcare Inc.是一家美国企业，主营非处方健康护理产品及家用清洁产品的营销与分销业务。该公司于1996年由Medtech Products、Prestige Brands International及Spic and Span三家公司合并成立，总部位于纽约州塔里敦，在弗吉尼亚州林奇堡设有生产工厂。
GLPI vs PBH — 直观对比
损益表 — Q1 FY2026 vs Q3 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $420.0M | $283.4M |
| 净利润 | $239.4M | $46.7M |
| 毛利率 | — | 55.5% |
| 营业利润率 | 79.4% | 29.1% |
| 净利率 | 57.0% | 16.5% |
| 营收同比 | 6.3% | -2.4% |
| 净利润同比 | 40.5% | -23.5% |
| 每股收益（稀释后） | — | $0.97 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q1 26 | $420.0M | — | ||
| Q4 25 | $407.0M | $283.4M | ||
| Q3 25 | $397.6M | $274.1M | ||
| Q2 25 | $394.9M | $249.5M | ||
| Q1 25 | $395.2M | $296.5M | ||
| Q4 24 | $389.6M | $290.3M | ||
| Q3 24 | $385.3M | $283.8M | ||
| Q2 24 | $380.6M | $267.1M |
| Q1 26 | $239.4M | — | ||
| Q4 25 | $275.4M | $46.7M | ||
| Q3 25 | $241.2M | $42.2M | ||
| Q2 25 | $151.4M | $47.5M | ||
| Q1 25 | $165.2M | $50.1M | ||
| Q4 24 | $223.6M | $61.0M | ||
| Q3 24 | $184.7M | $54.4M | ||
| Q2 24 | $208.3M | $49.1M |
| Q1 26 | — | — | ||
| Q4 25 | — | 55.5% | ||
| Q3 25 | — | 55.3% | ||
| Q2 25 | — | 56.2% | ||
| Q1 25 | — | 57.3% | ||
| Q4 24 | — | 55.5% | ||
| Q3 24 | — | 55.5% | ||
| Q2 24 | — | 54.7% |
| Q1 26 | 79.4% | — | ||
| Q4 25 | 89.3% | 29.1% | ||
| Q3 25 | 84.8% | 29.1% | ||
| Q2 25 | 61.3% | 28.8% | ||
| Q1 25 | 65.5% | 29.8% | ||
| Q4 24 | 79.1% | 31.7% | ||
| Q3 24 | 70.4% | 29.7% | ||
| Q2 24 | 77.1% | 27.0% |
| Q1 26 | 57.0% | — | ||
| Q4 25 | 67.6% | 16.5% | ||
| Q3 25 | 60.7% | 15.4% | ||
| Q2 25 | 38.4% | 19.0% | ||
| Q1 25 | 41.8% | 16.9% | ||
| Q4 24 | 57.4% | 21.0% | ||
| Q3 24 | 47.9% | 19.2% | ||
| Q2 24 | 54.7% | 18.4% |
| Q1 26 | — | — | ||
| Q4 25 | $0.96 | $0.97 | ||
| Q3 25 | $0.85 | $0.86 | ||
| Q2 25 | $0.54 | $0.95 | ||
| Q1 25 | $0.60 | $1.00 | ||
| Q4 24 | $0.79 | $1.22 | ||
| Q3 24 | $0.67 | $1.09 | ||
| Q2 24 | $0.77 | $0.98 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $274.5M | $62.4M |
| 总债务越低越好 | — | $1.0B |
| 股东权益账面价值 | $5.0B | $1.8B |
| 总资产 | $13.8B | $3.5B |
| 负债/权益比越低杠杆越低 | — | 0.56× |
8季度趋势，按日历期对齐
| Q1 26 | $274.5M | — | ||
| Q4 25 | — | $62.4M | ||
| Q3 25 | — | $119.1M | ||
| Q2 25 | — | $139.5M | ||
| Q1 25 | — | $97.9M | ||
| Q4 24 | $560.8M | $50.9M | ||
| Q3 24 | $560.8M | $51.5M | ||
| Q2 24 | $560.8M | $34.3M |
| Q1 26 | — | — | ||
| Q4 25 | $7.2B | $1.0B | ||
| Q3 25 | $7.2B | $993.1M | ||
| Q2 25 | $6.9B | $992.7M | ||
| Q1 25 | $6.9B | $992.4M | ||
| Q4 24 | $7.7B | $992.0M | ||
| Q3 24 | $7.4B | $1.1B | ||
| Q2 24 | $6.6B | $1.1B |
| Q1 26 | $5.0B | — | ||
| Q4 25 | $4.6B | $1.8B | ||
| Q3 25 | $4.6B | $1.8B | ||
| Q2 25 | $4.6B | $1.9B | ||
| Q1 25 | $4.2B | $1.8B | ||
| Q4 24 | $4.3B | $1.8B | ||
| Q3 24 | $4.3B | $1.7B | ||
| Q2 24 | $4.1B | $1.7B |
| Q1 26 | $13.8B | — | ||
| Q4 25 | $12.9B | $3.5B | ||
| Q3 25 | $12.8B | $3.4B | ||
| Q2 25 | $12.5B | $3.4B | ||
| Q1 25 | $12.1B | $3.4B | ||
| Q4 24 | $13.1B | $3.3B | ||
| Q3 24 | $12.7B | $3.3B | ||
| Q2 24 | $11.8B | $3.3B |
| Q1 26 | — | — | ||
| Q4 25 | 1.56× | 0.56× | ||
| Q3 25 | 1.57× | 0.54× | ||
| Q2 25 | 1.51× | 0.54× | ||
| Q1 25 | 1.63× | 0.54× | ||
| Q4 24 | 1.81× | 0.55× | ||
| Q3 24 | 1.74× | 0.61× | ||
| Q2 24 | 1.60× | 0.65× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $78.3M |
| 自由现金流经营现金流 - 资本支出 | — | $75.3M |
| 自由现金流率自由现金流/营收 | — | 26.6% |
| 资本支出强度资本支出/营收 | — | 1.1% |
| 现金转化率经营现金流/净利润 | — | 1.68× |
| 过去12个月自由现金流最近4个季度 | — | $267.2M |
8季度趋势，按日历期对齐
| Q1 26 | — | — | ||
| Q4 25 | $1.1B | $78.3M | ||
| Q3 25 | $240.3M | $57.5M | ||
| Q2 25 | $293.4M | $79.0M | ||
| Q1 25 | $252.5M | $61.8M | ||
| Q4 24 | $1.1B | $65.1M | ||
| Q3 24 | $270.4M | $69.8M | ||
| Q2 24 | $252.1M | $54.8M |
| Q1 26 | — | — | ||
| Q4 25 | — | $75.3M | ||
| Q3 25 | $183.0M | $55.4M | ||
| Q2 25 | $272.3M | $78.2M | ||
| Q1 25 | $239.6M | $58.4M | ||
| Q4 24 | $1.1B | $63.5M | ||
| Q3 24 | $261.5M | $67.8M | ||
| Q2 24 | $245.0M | $53.6M |
| Q1 26 | — | — | ||
| Q4 25 | — | 26.6% | ||
| Q3 25 | 46.0% | 20.2% | ||
| Q2 25 | 69.0% | 31.3% | ||
| Q1 25 | 60.6% | 19.7% | ||
| Q4 24 | 275.3% | 21.9% | ||
| Q3 24 | 67.9% | 23.9% | ||
| Q2 24 | 64.4% | 20.1% |
| Q1 26 | — | — | ||
| Q4 25 | — | 1.1% | ||
| Q3 25 | 14.4% | 0.8% | ||
| Q2 25 | 5.3% | 0.3% | ||
| Q1 25 | 3.3% | 1.2% | ||
| Q4 24 | 0.0% | 0.5% | ||
| Q3 24 | 2.3% | 0.7% | ||
| Q2 24 | 1.9% | 0.4% |
| Q1 26 | — | — | ||
| Q4 25 | 4.10× | 1.68× | ||
| Q3 25 | 1.00× | 1.36× | ||
| Q2 25 | 1.94× | 1.66× | ||
| Q1 25 | 1.53× | 1.23× | ||
| Q4 24 | 4.80× | 1.07× | ||
| Q3 24 | 1.46× | 1.28× | ||
| Q2 24 | 1.21× | 1.12× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
GLPI
暂无分部数据
PBH
| Womens Health | $51.8M | 18% |
| International OTC Healthcare | $47.7M | 17% |
| Gastrointestinal | $44.2M | 16% |
| Eye And Ear Care | $35.2M | 12% |
| Dermatologicals | $27.6M | 10% |
| Analgesics | $26.7M | 9% |
| Oral Care | $23.5M | 8% |
| Cough And Cold | $23.0M | 8% |
| Other Otc | $3.6M | 1% |
